Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cassava Sciences ( (SAVA) ) has provided an update.
Between August 27 and October 26, 2021, four putative federal securities class actions were filed against Cassava Sciences and certain officers in the U.S. District Court for the Western District of Texas, later consolidated on June 30, 2022 into a single case covering purchasers and sellers of the company’s common stock and options from September 14, 2020 to October 12, 2023. On December 19, 2025, following mediation, Cassava and its CFO Eric J. Schoen agreed via a binding term sheet to pay $31.25 million into escrow, expected in January 2026, to fully settle all claims in the consolidated action in exchange for complete releases for the company and the individually named officers, with the company having already reserved the full settlement amount as a loss contingency in the second quarter of 2025 and seeking court approval for the settlement, which does not constitute an admission of wrongdoing.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences is a biopharmaceutical company whose securities, including common stock and related options, are publicly traded and subject to U.S. federal securities laws, with an investor base that includes purchasers and sellers of its equity and derivatives over defined class periods relevant to securities litigation.
Average Trading Volume: 1,933,796
Technical Sentiment Signal: Strong Sell
Current Market Cap: $105.1M
For a thorough assessment of SAVA stock, go to TipRanks’ Stock Analysis page.